Targeted opening of the blood-brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma

Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination fails against glioblastoma, hidden behind the blood-brain barrier (BBB). A recent work delineates a biophysical method for BBB p...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2024-12, Vol.13 (1), p.2385124
Main Authors: Pol, Jonathan G., Lizarralde-Guerrero, Manuela, Checcoli, Andrea, Kroemer, Guido
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Blood-brain barrier
Blood-Brain Barrier - drug effects
Blood-Brain Barrier - metabolism
Brain Neoplasms - drug therapy
Brain Neoplasms - immunology
Brain Neoplasms - metabolism
Brain Neoplasms - pathology
Brain Neoplasms - therapy
cancer immunotherapy
Comment
doxorubicin
Doxorubicin - administration & dosage
Doxorubicin - pharmacology
Doxorubicin - therapeutic use
Glioblastoma - drug therapy
Glioblastoma - immunology
Glioblastoma - metabolism
Glioblastoma - pathology
Humans
immune checkpoint inhibitor
Immune Checkpoint Inhibitors - pharmacology
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy - methods
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Programmed Cell Death 1 Receptor - metabolism
ultrasounds
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination fails against glioblastoma, hidden behind the blood-brain barrier (BBB). A recent work delineates a biophysical method for BBB permeabilization that yields effective preclinical effects of chemoimmunotherapy.
ISSN:2162-402X
2162-4011
2162-402X
DOI:10.1080/2162402X.2024.2385124